You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

 

Online download statistics by month:

Online download statistics by month: March 2021 to February 2026

AbstractFullPdf
Mar 2021297297127
Apr 2021306306134
May 202115315248
Jun 202112112146
Jul 202112112147
Aug 202110510538
Sep 202110310341
Oct 202111411455
Nov 2021908946
Dec 2021919231
Jan 2022687838
Feb 2022434438
Mar 2022708556
Apr 2022576539
May 2022474832
Jun 2022434628
Jul 2022535629
Aug 2022959745
Sep 2022565731
Oct 2022586444
Nov 2022474723
Dec 2022313219
Jan 2023444422
Feb 2023777925
Mar 2023464623
Apr 2023717121
May 2023798229
Jun 2023444418
Jul 2023616123
Aug 2023383817
Sep 2023515234
Oct 2023525224
Nov 2023434313
Dec 2023404022
Jan 2024333422
Feb 2024505135
Mar 2024313145
Apr 2024525233
May 2024525430
Jun 2024444323
Jul 2024505128
Aug 2024282720
Sep 2024363619
Oct 2024626249
Nov 2024394131
Dec 2024475021
Jan 2025515126
Feb 2025363623
Mar 2025454529
Apr 2025727233
May 2025575941
Jun 2025575727
Jul 2025110
Feb 2026110
Total365937251841